Home » Stocks » Aduro BioTech

Aduro BioTech, Inc. (ADRO)

Stock Price: $2.51 USD 0.03 (1.01%)
Updated Aug 14, 2020 10:57 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 202.50M
Revenue (ttm) 27.96M
Net Income (ttm) -66.52M
Shares Out 81.06M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.51
Previous Close $2.48
Change ($) 0.03
Change (%) 1.01%
Day's Open 2.43
Day's Range 2.40 - 2.55
Day's Volume 211,666
52-Week Range 0.90 - 4.04

More Stats

Market Cap 202.50M
Enterprise Value 32.13M
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 81.06M
Float 46.75M
EPS (basic) -0.82
EPS (diluted) -0.80
FCF / Share -0.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.26M
Short Ratio 9.17
Short % of Float 5.84%
Beta 0.40
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 7.24
PB Ratio 4.30
Revenue 27.96M
Operating Income -79.37M
Net Income -66.52M
Free Cash Flow -63.05M
Net Cash 170.37M
Net Cash / Share 2.11
Gross Margin -173.88%
Operating Margin -283.91%
Profit Margin -243.90%
FCF Margin -225.53%
ROA -13.90%
ROE -87.44%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

Current: $2.51
Target: 3.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth14.39%-12.48%-65.99%-30.55%445.07%1517.03%-
Gross Profit17.2615.0917.2450.6872.9813.390.83
Operating Income-90.14-101-106-71.86-13.56-19.12-14.54
Net Income-82.37-95.36-91.86-91.15-39.21-17.01-16.05
Shares Outstanding80.1178.8172.9065.2044.710.320.29
Earnings Per Share-1.03-1.21-1.26-1.40-0.88-53.06-55.80
Operating Cash Flow-65.51-68.76-88.86-86.0815519.37-14.23
Capital Expenditures-1.26-2.32-5.15-23.89-2.17-0.78-0.17
Free Cash Flow-66.77-71.08-94.01-11015318.58-14.40
Cash & Equivalents2142673273484161198.53
Total Debt33.44-----12.99
Net Cash / Debt181267327348416119-4.46
Book Value65.60135237227262-61.30-38.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aduro BioTech, Inc.
Country United States
Employees 69
CEO Stephen T. Isaacs

Stock Information

Ticker Symbol ADRO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ADRO
IPO Date April 15, 2015


Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation clinical trial and Phase Ib dose escalation clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase II clinical trial in combination with pembrolizumab, an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and natural killer cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; and license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro Biotech, Inc. in June 2008. Aduro Biotech, Inc. was founded in 2000 and is headquartered in Berkeley, California.